Peginterferon beta-1a

Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis.^[4][5]

Peginterferon beta-1a

Clinical data
Trade names	Plegridy, Plegridy Pen
Other names	BIIB-017
AHFS/Drugs.com	Monograph
MedlinePlus	a614059
License data	US DailyMed: Peginterferon beta-1a
Pregnancy category	AU: D[1]
Routes of administration	Subcutaneous injection
Drug class	Antineoplastic agent
ATC code	L03AB13 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[2] CA: ℞-only[3] US: ℞-only[4] EU: Rx-only[5] In general: ℞ (Prescription only)
Identifiers
IUPAC name 1-Ether with N-(3-hydroxy-2-methylpropyl)interferon β-1a (human) α-methyl-ω-hydroxy-poly(oxy-1,2-ethanediyl)
CAS Number	1211327-92-2
DrugBank	DB09122
UNII	I8309403R0
KEGG	D10483
Chemical and physical data
Formula	C913H1417N246O256PS7 [C2H4O]n
Molar mass	44000 g·mol−1

The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.^[4][5]

Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014.^[6][5]

Medical uses

In the United States, peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.^[4]

In the European Union, peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.^[5]